<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35254428</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1945-7197</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>107</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>17</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical endocrinology and metabolism</Title>
          <ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Should Dehydroepiandrosterone Be Administered to Women?</ArticleTitle>
        <Pagination>
          <StartPage>1679</StartPage>
          <EndPage>1685</EndPage>
          <MedlinePgn>1679-1685</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1210/clinem/dgac130</ELocationID>
        <Abstract>
          <AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Androgen prohormones such as dehydroepiandrosterone (DHEA) increase in early puberty, peak in the second and third decade, and thereafter decline, independent of menopausal status. Investigators have examined their potential beneficial effects in normal women and those with DHEA-deficient states.</AbstractText>
          <AbstractText Label="EVIDENCE ACQUISITION" NlmCategory="METHODS">A review of the literature from 1985 to 2021 on the potential benefits and risks of androgen prohormones in women.</AbstractText>
          <AbstractText Label="EVIDENCE SYNTHESIS" NlmCategory="RESULTS">Studies have examined the potential benefit of DHEA therapy for anti-aging, sexual dysfunction, infertility, metabolic bone health, cognition, and wellbeing in hormone-deficient states such as primary adrenal insufficiency, hypopituitarism, and anorexia as well as administration to normal women across the lifespan.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Data support small benefits in quality of life and mood but not for anxiety or sexual function in women with primary or secondary adrenal insufficiency or anorexia. No consistent beneficial effects of DHEA administration have been observed for menopausal symptoms, sexual function, cognition, or overall wellbeing in normal women. Local administration of DHEA shows benefit in vulvovaginal atrophy. Use of DHEA to improve induction of ovulation response in women with diminished ovarian reserve is not recommended. Risks of high physiologic or pharmacologic use of DHEA include androgenic and estrogenic side effects which are of concern for long-term administration.</AbstractText>
          <AbstractText Label="CLINICAL CASE" NlmCategory="METHODS">A 49-year-old woman with Addison's disease who is on low dose estrogen with cyclic progesterone therapy for menopausal symptoms returns for follow-up. She is on a stable glucocorticoid replacement strategy of hydrocortisone 10 mg in the morning and 5 mg in the early afternoon and fludrocortisone 0.05 mg each morning. She has read on the internet that additional therapy with DHEA may help her overall quality of life and libido. She asks whether she should add this therapy to her regimen and at what dose.</AbstractText>
          <CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wierman</LastName>
            <ForeName>Margaret E</ForeName>
            <Initials>ME</Initials>
            <Identifier Source="ORCID">0000-0002-7634-1093</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kiseljak-Vassiliades</LastName>
            <ForeName>Katja</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-3341-582X</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO 80045, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>I01 BX004665</GrantID>
            <Acronym>BX</Acronym>
            <Agency>BLRD VA</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K08CA222620</GrantID>
            <Acronym>BC</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Endocrinol Metab</MedlineTA>
        <NlmUniqueID>0375362</NlmUniqueID>
        <ISSNLinking>0021-972X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000728">Androgens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004967">Estrogens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459AG36T1B</RegistryNumber>
          <NameOfSubstance UI="D003687">Dehydroepiandrosterone</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000728" MajorTopicYN="Y">Androgens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000855" MajorTopicYN="N">Anorexia</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003687" MajorTopicYN="Y">Dehydroepiandrosterone</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020249" MajorTopicYN="N">Hormone Replacement Therapy</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">DHEA</Keyword>
        <Keyword MajorTopicYN="N">androstenedione</Keyword>
        <Keyword MajorTopicYN="N">hormonal therapies</Keyword>
        <Keyword MajorTopicYN="N">testosterone</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>12</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35254428</ArticleId>
        <ArticleId IdType="pmc">PMC9113789</ArticleId>
        <ArticleId IdType="doi">10.1210/clinem/dgac130</ArticleId>
        <ArticleId IdType="pii">6543726</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Lieberman S. An abbreviated account of some aspects of the biochemistry of DHEA, 1934-1995. Ann N Y Acad Sci. 1995;774:1-15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8597450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014;74(11):1195-1207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25022952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baulieu EE, Corpechot C, Dray F, et al. . 
An adrenal-secreted “androgen”: dehydroisoandrosterone sulfate. its metabolism and a tentative generalization on the metabolism of other steroid conjugates in man. Recent Prog Horm Res. 1965;21:411-500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14321064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prall SP, Muehlenbein MP. DHEA modulates immune function: a review of evidence. Vitam Horm. 2018;108:125-144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30029724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Coles AJ, Thompson S, Cox AL, Curran S, Gurnell EM, Chatterjee VK. Dehydroepiandrosterone replacement in patients with Addison’s disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells. Eur J Immunol. 2005;35(12):3694-3703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16252254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Longcope C. Adrenal and gonadal androgen secretion in normal females. Clin Endocrinol Metab 1986;15(2):213-228.</Citation>
        </Reference>
        <Reference>
          <Citation>
Burger HG. Androgen production in women. Fertil Steril. 2002;77(Suppl 4):S3-S5.</Citation>
        </Reference>
        <Reference>
          <Citation>
Horton R, Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest. 1966;45(3):301-313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC292699</ArticleId>
            <ArticleId IdType="pubmed">5904549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Migeon CJ, Keller AR, Lawrence B, Shepard TH, 2nd. Dehydroepiandrosterone and androsterone levels in human plasma: effect of age and sex; day-to-day and diurnal variations. J Clin Endocrinol Metab. 1957;17(9):1051-1062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13463066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59(3):551-555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6235241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Turcu AF, Rege J, Auchus RJ, Rainey WE. 11-Oxygenated androgens in health and disease. Nat Rev Endocrinol. 2020;16(5):284-296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7881526</ArticleId>
            <ArticleId IdType="pubmed">32203405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schiffer L, Arlt W, Storbeck KH. Intracrine androgen biosynthesis, metabolism and action revisited. Mol Cell Endocrinol. 2018;465:4-26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6565845</ArticleId>
            <ArticleId IdType="pubmed">28865807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thompson RD, Carlson M, Thompson RD, Carlson M. Liquid chromatographic determination of dehydroepiandrosterone (DHEA) in dietary supplement products. J AOAC Int. 2000;83(4):847-857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10995111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab. 1988;66(1):57-61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2961787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Legrain S, Massien C, Lahlou N, et al. . 
Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J Clin Endocrinol Metab. 2000;85(9):3208-3217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10999810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab. 1990;71(3):696-704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2144295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baulieu EE, Thomas G, Legrain S, et al. . 
Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA. 2000;97(8):4279-4284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC18228</ArticleId>
            <ArticleId IdType="pubmed">10760294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Percheron G, Hogrel JY, Denot-Ledunois S, et al. ; Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med. 2003;163(6):720-727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12639206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nair KS, Rizza RA, O’Brien P, et al. . 
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355(16):1647-1659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17050889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wolf OT, Kudielka BM, Hellhammer DH, Hellhammer J, Kirschbaum C. Opposing effects of DHEA replacement in elderly subjects on declarative memory and attention after exposure to a laboratory stressor. Psychoneuroendocrinology 1998;23(6):617-629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9802132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
von Muhlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int. 2008;19(5):699-707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2435090</ArticleId>
            <ArticleId IdType="pubmed">18084691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hirshman E, Wells E, Wierman ME, et al. . 
The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. Psychon Bull Rev. 2003;10(1):125-134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12747499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grimley Evans J, Malouf R, Huppert F, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev. 6221;2006(4):CD006221.</Citation>
        </Reference>
        <Reference>
          <Citation>
Barnhart KT, Freeman E, Grisso JA, et al. . 
The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab. 1999;84(11):3896-3902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10566625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev. 2015;1:CD011066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25879093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Arlt W. The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab. 2009;94(4):1059-1067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19349469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Arlt W, Callies F, van Vlijmen JC, et al. . 
Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341(14):1013-1020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10502590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hunt PJ, Gurnell EM, Huppert FA, et al. . 
Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double blind trial. J Clin Endocrinol Metab. 2000;85(12):4650-4656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11134123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lovas K, Gebre-Medhin G, Trovik TS, et al. . 
Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab. 2003;88(3):1112-1118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12629093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gurnell EM, Hunt PJ, Curran SE, et al. . 
Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab. 2008;93(2):400-409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2729149</ArticleId>
            <ArticleId IdType="pubmed">18000094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Binder G, Weber S, Ehrismann M, et al. ; South German Working Group for Pediatric Endocrinology. Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well-being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial. J Clin Endocrinol Metab. 2009;94(4):1182-1190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19126625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Johannsson G, Burman P, Wiren L, et al. . 
Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial. J Clin Endocrinol Metab. 2002;87(5):2046-2052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11994339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
van Thiel SW, Romijn JA, Pereira AM, et al. . 
Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. J Clin Endocrinol Metab. 2005;90(6):3295-3303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15797966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alkatib AA, Cosma M, Elamin MB, et al. . 
A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab. 2009;94(10):3676-3681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19773400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Misra M, Klibanski A. Endocrine consequences of anorexia nervosa. Lancet Diabetes Endocrinol. 2014;2(7):581-592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4133106</ArticleId>
            <ArticleId IdType="pubmed">24731664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gordon CM, Grace E, Emans SJ, et al. . 
Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab. 2002;87(11):4935-4941.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12414853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gordon CM, Grace E, Emans SJ, Goodman E, Crawford MH, Leboff MS. Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa. J Bone Miner Res. 1999;14(1):136-145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9893076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Elraiyah T, Sonbol MB, Wang Z, et al. . 
Clinical review: the benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3536-3542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5393492</ArticleId>
            <ArticleId IdType="pubmed">25279571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wierman ME, Arlt W, Basson R, et al. . 
Androgen therapy in women: a reappraisal: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25279570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Davis SR, Baber R, Panay N, et al. . 
Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6821450</ArticleId>
            <ArticleId IdType="pubmed">31498871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wierman ME, Basson R, Davis SR, et al. . 
Androgen therapy in women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(10):3697-3710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17018650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Costello MF, Misso ML, Balen A, et al. . 
Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility. Hum Reprod Open 2019;2019(1):hoy021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6396642</ArticleId>
            <ArticleId IdType="pubmed">31486807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
de Wit AE, Giltay EJ, de Boer MK, et al. . 
Plasma androgens and the presence and course of depression in a large cohort of women. Transl Psychiatry. 2021;11(1):124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7881099</ArticleId>
            <ArticleId IdType="pubmed">33579903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Peixoto C, Grande AJ, Mallmann MB, Nardi AE, Cardoso A, Veras AB. Dehydroepiandrosterone (DHEA) for depression: a systematic review and meta-analysis. CNS Neurol Disord Drug Targets. 2018;17(9):706-711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30124161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jankowski CM, Wolfe P, Schmiege SJ, et al. . 
Sex-specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: A pooled analysis of four clinical trials. Clin Endocrinol (Oxf) 2019;90(2):293-300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6336516</ArticleId>
            <ArticleId IdType="pubmed">30421439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jankowski CM, Gozansky WS, Kittelson JM, Van Pelt RE, Schwartz RS, Kohrt WM. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. J Clin Endocrinol Metab. 2008;93(12):4767-4773.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2626446</ArticleId>
            <ArticleId IdType="pubmed">18812486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. J Clin Endocrinol Metab. 2011;96(6):1642-1653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21411558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998;49(4):421-432.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9876338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen H, Jin Z, Sun C, Santos HO, Kord Varkaneh H. Effects of dehydroepiandrosterone (DHEA) supplementation on cortisol, leptin, adiponectin, and liver enzyme levels: a systematic review and meta-analysis of randomised clinical trials. Int J Clin Pract. 4698;2021:e1.</Citation>
        </Reference>
        <Reference>
          <Citation>
Clark BJ, Prough RA, Klinge CM. Mechanisms of action of dehydroepiandrosterone. Vitam Horm. 2018;108:29-73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30029731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 2004;292(18):2243-2248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15536111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Climacteric. 2014;17(5):557-563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25153131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Labrie F, Martel C, Berube R, et al. . 
Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Steroid Biochem Mol Biol. 2013;138:359-367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23954500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause 2017;24(11):1246-1256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28640161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Archer DF, Labrie F, Montesino M, Martel C. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10µg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol. 2017;174:1-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28323042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Faubion SS, Larkin LC, Stuenkel CA, et al. . 
Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Women’s Sexual Health. Menopause 2018;25(6):596-608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29762200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol. 2011;9(9):67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3112409</ArticleId>
            <ArticleId IdType="pubmed">21586137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Qin JC, Fan L, Qin AP. The effect of dehydroepiandrosterone (DHEA) supplementation on women with diminished ovarian reserve (DOR) in IVF cycle: Evidence from a meta-analysis. J Gynecol Obstet Hum Reprod 2017;46(1):1-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28403950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schwarze JE, Canales J, Crosby J, Ortega-Hrepich C, Villa S, Pommer R. DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: a systematic review and meta-analysis. JBRA Assist Reprod 2018;22(4):369-374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6210617</ArticleId>
            <ArticleId IdType="pubmed">30125071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Buisson C, Frelat C, Privat K, Martinat N, Audran M, Collomp K. Metabolic and isotopic signature of short-term DHEA administration in women: comparison with findings in men. Drug Test Anal. 2018;10(11-12):1744-1754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30315670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bentley C, Potter C, Yakoub KM, et al. . 
A prospective, phase II, single-centre, cross-sectional, randomised study investigating dehydroepiandrosterone supplementation and its profile in trauma: ADaPT. BMJ Open 2021;11(7):e040823.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
